– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets 

– Company publishes Q1 2026 financial results with revenue in line with prior guidance & substantial year-on-year gross margin percentage improvements            

DUBLIN, June 16, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received additional purchase orders for over 2 million units of its flagship rapid HIV test, TrinScreen™ HIV. These orders are scheduled for fulfillment in Q3 2026 and are expected to make a meaningful contribution to the Company's 2026 revenue and profitability objectives.

These orders provide further evidence of renewed, broad-based demand for rapid HIV diagnostics across global health markets, following disruptions in 2025 due to changes affecting international aid funding structures.

TrinScreen™ HIV is a WHO prequalified point of care diagnostic test designed for use in high-volume community screening programs in countries with high HIV prevalence, offering reliable results and ease of use in diverse clinical settings. These orders will be manufactured under the new offshored and outsourced manufacturing process, a key deliverable in the Company's Comprehensive Transformation Plan, which provides for efficient and cost-effective scalability.